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Abstract
Introduction: The goal of this study is to investigate whether the -308G > A promoter polymorphism in the tumor
necrosis factor alpha (TNFA) gene is associated with disease severity and radiologic joint damage in a large cohort
of patients with rheumatoid arthritis (RA).
Methods: A long-term observational early RA inception cohort (n = 208) with detailed information about disease
activity and radiologic damage after 3, 6 and 9 years of disease was genotyped for the TNFA -308G > A promoter
polymorphism (rs1800629). A longitudinal regression analysis was performed to assess the effect of genotype on
RA disease severity and joint damage. Subsequently, a meta-analysis, including all publically available data, was
performed to further test the association between joint erosions and the TNFA polymorphism. To learn more about
the mechanism behind the effect of the polymorphism, RNA isolated from peripheral blood from RA patients (n =
66) was used for TNFA gene expression analysis by quantitative PCR.
Results: Longitudinal regression analysis with correction for gender and disease activity showed a significant
difference in total joint damage between GG and GA+AA genotype groups (P = 0.002), which was stable over
time. The meta-analysis, which included 2,053 patients, confirmed an association of the genetic variant with the
development of erosions (odds ratio 0.78, 95% CI 0.62, 0.98). No significant differences in TNFA gene expression
were observed for the different genotypes, confirming earlier findings in healthy individuals.
Conclusions: Our data confirm that the TNFA -308G > A promoter polymorphism is associated with joint damage
in patients with RA. This is not mediated by differences in TNFA gene expression between genotypes.
Introduction
TNF plays a key role in the pathogenesis of rheumatoid
arthritis (RA) and other auto-immune diseases. Several
genetic variants in the TNFA gene, which codes for
TNFa, have been investigated in relation to disease
severity, but none of them appears to be highly specific
and/or sensitive. The most thoroughly investigated
TNFA polymorphism is the -308G > A (rs1800629)
located in the promoter of the gene, though studies
focusing on this polymorphism have yielded conflicting
results, [1-14].
Three studies [3,6,7] showed an association of the G
allele with more pronounced radiologic joint damage.
Other studies reported a worse radiologic outcome in
patients carrying the A allele [1,9,13], or no association
between the genetic variant and radiologic progression
[2,8-12,14]. Given the contradictory results in these rela-
tively small, individual studies, there is a need for a more
comprehensive approach to evaluate the presence or
absence of an association between the TNFA -308G > A
polymorphism and the severity of RA and radiological
joint damage.
As the -308G > A variant is located within the TNFA
promoter, several studies have also investigated the poly-
morphism in relation to TNFA transcription, which
could influence TNFa production and in turn, disease
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activity and severity [2,15-23]. An important study by
Knight et al., using the haploChIP method for high-
throughput screening of common DNA polymorphisms
that (might) effect gene regulation in vivo, reported that
the -308G > A polymorphism was not associated with
TNFA expression in human B-cells [24]. A recent meta-
analysis in healthy individuals (n = 1,825) shows that
TNFa mRNA and protein levels are not influenced by
the polymorphism [25].
Here, we first investigated the possible associations of
the -308G > A promoter polymorphism with disease activ-
ity, and radiologic joint damage after 3, 6 and 9 years
follow-up in a large (n = 208), well-characterized cohort of
patients with early RA [26]. Next, we performed a meta-
analysis to draw more definitive conclusions on the role of
the TNFA -308G > A polymorphism in the severity of RA
and radiological joint damage. This meta-analysis included
a total of 2,053 patients and combined our data with pre-
viously published studies. To evaluate possible mechan-
isms underlying an association, we investigated gene
expression in the different genotype groups in a cohort of
66 individuals with active RA.
Material and methods
Ethics statement
The Commissie Mensgebonden Onderzoek (CMO) Regio
Arnhem Nijmegen of the Radboud University Nijmegen
Medical Centre approved the study (CMO number 2004/
014). All patients had provided written informed consent
prior to participation in the study. All clinical investiga-
tions were conducted according to the principles
expressed in the Declaration of Helsinki.
Patients
All patients in this study fulfilled the 1987 American Col-
lege of Rheumatology (ACR) criteria for RA and attended
the Department of Rheumatology of the Radboud Univer-
sity Nijmegen Medical Centre or the St. Maartenshospital
in Nijmegen, The Netherlands.
The impact of the TNFA -308G > A polymorphism on
disease severity was analyzed using DNA isolated from
blood of 208 patients from a long-term observational
inception cohort with early RA [26]. Patients in this cohort
have a disease duration < 1 year and no prior use of
DMARDs at enrollment. Disease activity was assessed
using the 28-joint disease activity score (DAS28) at each
3-monthly visit. Radiologic joint damage at baseline and
after 1, 2, 3, 6 and 9 years of disease duration was mea-
sured using radiographs of the hands and feet, read in
chronological order by one of four raters according to the
Ratingen score. The latter is a validated modification of
the Larsen score and evaluates joint surface destruction,
graded from 0 to 5, in 38 separate hand and foot joints
(range 0 - 190) [27]. The intra-class correlation coefficient
(ICC) for inter-rater reliability was 0.85; this was tested
previously with the four raters in 10 patients over 9 years.
TNFA expression analysis was assessed in RNA from
blood of 66 additional patients with active RA as defined
by DAS28 > 3.2. All patients attended the same hospital,
and blood for RNA isolation was always collected between
9 and 10 o’clock in the morning to avoid potential circa-
dian fluctuations.
Molecular analysis
All DNA and RNA analyses were performed in a Coördi-
natie Commissie ter bevordering van de Kwaliteitsbeheer-
sing van het Laboratoriumonderzoek (CCKL)-accredited
laboratory at the department of Human Genetics at
the Radboud University Nijmegen Medical Centre in
Nijmegen.
Genotyping of the -308G > A TNFA polymorphism
Genomic DNA was extracted from peripheral venous
blood (10 ml/sample) according to standard protocols
[28]. Both patient cohorts, thus, a total of 274 patients,
were genotyped for the -308G > A (rs1800629) promo-
ter polymorphism using a TaqMan genotyping assay
(ID: C7514879_10) on the 7500 Fast Real-Time PCR
system (Applied Biosystems, Foster City, CA, USA).
Results were analyzed using Allelic Discrimination soft-
ware version 1.4 (Applied Biosystems).
RNA isolation, synthesis of cDNA and quantitative PCR
RNA was isolated from whole blood within 30 minutes
after collection, using the RNeasy midi kit (Qiagen Bene-
lux BV Venlo, The Netherlands). The quality and quantity
of the purified RNA was checked on a NanoDrop spectro-
photometer (Nanodrop technologies, Montchanin, DE,
USA). Degradation of RNA was controlled for by agarose
gel electrophoresis. Per sample, 1 μg of total RNA was
reverse-transcribed using 200 ng random hexanucleotides
(Invitrogen, Breda, The Netherlands) and 200 units of
moloney murine leukemia virus (M-MLV) Reverse Tran-
scriptase (Invitrogen). For quantitative expression analysis
a predesigned and validated gene-specific probe-based
TaqMan gene expression assay (ID: Hs00174128_m1) was
used according to the manufacturer’s protocol (Applied
Biosystems). Samples were run on the 7500 Fast Real-
Time PCR System (Applied Biosystems) using standard
protocols. The general housekeeping gene B2M (Beta-2-
microglobulin, TaqMan gene expression assay ID:
Hs99999907_m1) was used as the endogenous control.
Threshold cycle numbers (referred to as Ct) were obtained
using the 7500 System SDS software version 1.4 (Applied
Biosystems). All samples were measured twice, and dupli-
cate samples with a SD larger than 0.5 were excluded
from the analysis. The relative quantity (RQ) of the gene-
specific mRNA was calculated from the average value of
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the ΔCt ((TNFA Ct) - (endogenous control gene Ct)). Dif-
ferences in expression between two groups of samples
were calculated by the 2ΔΔCt method [29].
Statistical analysis
Hardy-Weinberg equilibrium (HWE) was tested in both
patient samples using the chi square test. Baseline differ-
ences between genotype groups were analyzed using the
chi square test, Student’s t-test or Wilcoxon test, as appro-
priate. Longitudinal analysis of radiologic joint damage in
patients with RA was performed using generalized linear
regression models with random coefficients (mixed mod-
els), allowing for analysis of repeated measures within a
patient. The joint damage score was the dependent vari-
able, genotype the independent variable, under addition of
time, time squared and confounders. Regression assump-
tions were checked by evaluating the distribution of resi-
duals and by a plot of observed and predicted joint
damage scores. Mean differences in TNFA expression
(ΔCt; (TNFA Ct) - (endogenous control gene Ct)) were
analyzed using the independent Student’s t-test.
A P-value < 0.05 was considered statistically significant
in each situation. Analyses were performed using SPSS for
Windows, version 14.0 (SPSS, Chicago, IL, USA) and SAS
version 8.2 (SAS Institute Inc., Cary, NC, USA).
Meta-analysis
Pubmed (up to March 31, 2012) was searched to identify
publications investigating the effect of the -308G > A poly-
morphism on joint damage. Using the search terms: 1) RA
AND TNF AND (polymorphism or -308); 2) RA AND
joint damage AND (polymorphism or TNF or -308 and
TNF; 3) RA and erosions in combination with polymorph-
ism and TNF or -308. The literature search yielded 292
papers, 37 of which reported on relevant primary analysis
of the TNFA -308G > A polymorphism. In order to be
included in this meta-analysis, studies had to 1) include RA
patients according to the ACR criteria, and 2) report on
disease severity (presence or absence of erosions). Review
manager 5 was used to perform a meta-analysis including
11 studies (10 published ones and this study) [1-10].
Homogeneity of odds ratios (ORs) among cohorts was
calculated using the Breslow-Day method, and pooled
ORs were calculated under a fixed and random effects
model (Mantel-Haenszel meta-analysis).
Results
Relation of TNFA -308G > A with disease activity and
radiologic joint damage
The frequency of the A allele in the inception cohort was
18.3%, genotype frequencies were 66.3% for the GG
group, 30.8% for the GA group and 2.9% for the AA
group. Due to the small AA genotype group, the GA and
AA genotype groups were merged and analyzed as one
group. Demographic and disease characteristics were
similar in the GG and GA+AA genotype groups at base-
line (Table 1). No significant differences in disease activ-
ity were observed between genotype groups at baseline
(P = 0.38) and after 3 (P = 0.85), 6 (P = 0.1) and 9 (P =
0.12) years of follow-up.
In the longitudinal regression analysis (mixed model)
with radiologic joint damage as the dependent variable, a
significant difference between the GG and GA+AA groups
in the progression of joint damage was observed (Table 2
and Figure 1). As shown in Table 2, the progression of
joint damage in the patients was 1.6 points per year, with
progression rate slightly declining (-0.13 points) over the
years of study. At baseline, the joint damage score of the
genotype GA+AA group was on average 5 points lower
(P = 0.002) than the score of the GG genotype group,
Table 1 Demographics of the inception cohort (n = 208)
GG GA+AA
Number (n = 138) (n = 64 + 6) P-value
Age, years, mean (SD) 52 (13) 50 (13) 0.21
Female gender, n (%) 89 (64%) 50 (71%) 0.32
RF positivity, n (%) 105 (76%) 55 (79%) 0.69
DAS28, mean (SD)
Baseline 208 5.2 (1.4) 5.3 (1.3) 0.38
3-year average 208 4.0 (1.1) 3.9 (1.0) 0.85
6-year average 159 4.0 (1.0) 3.7 (1.0) 0.10
9-year average 115 4.0 (1.0) 3.7 (1.0) 0.12
Patients with erosions at baseline, n (%) 208 76 (55%) 44 (63%) 0.28
Ratingen score, median (range)
Baseline 208 0 (0-2) 0 (0-2) 0.17
3 years 208 7 (0-15) 4 (0-10) 0.08
6 years 160 12 (2-26) 10 (1-21) 0.18
9 years 116 22 (10-38) 14 (3-24) 0.07
Percentages are expressed in relation to the total number of patients for each genotype group. RF, rheumatoid factor; DAS28, 28-joint disease activity score.
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corrected for age and DAS28 at baseline. There was no
significant interaction between genotype and time of
study, that is, the difference in joint damage score between
genotype groups persisted during follow-up (P = 0.61),
although in Figure 1 it appears that the joint damage
scores of both groups converge at year-9.
Since TNF might uncouple the relation between disease
activity and joint damage [30], we assessed whether the
use of TNF blocking agents was frequent in this patient
population. The number of patients with past or present
treatment with these agents was low, and was similar in
both genotype groups (n = 20 (14%) and n = 12 (17%)) in
the GG and GA+AA groups, respectively.
Meta-analysis
A total of 2,053 RA patients from 10 published studies, as
well as the current one, were included in a meta-analysis
to further confirm the observed association of TNF -308G
> A with joint damage, in this case defined as the presence
or absence of erosions. Table 3 presents an overview of
characteristics and the definition of erosions of the studies
included in the meta-analysis. The analysis indeed con-
firmed that the -308G > A polymorphism is statistically
significantly associated with the presence of erosions (P =
0.04, OR 0.78, 95% CI 0.62, 0.98) (Figure 2), with patients
carrying the GA/AA genotypes having less erosions. As
we observed moderate heterogeneity, we also applied a
random effects meta-analysis, producing a similar OR
(0.86, 95% CI 0.58, 1.29).
TNFA expression and the role of the -308G > A promoter
polymorphism
To assess whether the difference in radiologic joint
damage between G-homozygotes and A-allele carriers
could be explained at the level of expression of this cyto-
kine, we measured the RNA expression levels of TNFA
dependent on -308G > A genotype in a sample of 66
patients with active RA. Among the sixty-six patients,
forty-nine carried the GG genotype, fifteen were GA-het-
erozygotes, and two were A-homozygotes. Again, the GA
and AA genotypes were merged and analyzed as one
group. No difference in TNFA expression was observed
between the GG group when compared to the GA+AA
group (P = 0.420) (Figure 3).
Discussion
Based on earlier literature, we tested the hypothesis that
in RA, disease severity defined by the average DAS28
and radiologic joint damage, may be influenced by the
TNFA -308G > A genotype. Our own study and the
meta-analysis indeed confirm that patients carrying the
common GG genotype have worse radiologic outcomes.
This could not be explained by differences in either dis-
ease activity, genotype-dependent TNFA expression, or
the use of TNF blocking agents.
Our results show that the GG genotype is associated
with a worse radiologic outcome, in spite of the fact that
in our early inception cohort the radiologic progression
after 9 years was similar in both genotypes. It would be of
great interest to see if these results could be replicated in
other early RA cohorts though the number of published
studies hitherto is too small for a meta-analysis.
Many studies investigating the relationship between the
-308G > A promoter polymorphism and severity of RA
and radiological joint damage report contradictive results
[1-14]. Therefore, a meta-analysis offers a good alternative
for evaluating the presence or absence of an association in
situations where individual studies are inconclusive. Our
meta-analysis indeed confirmed that the -308G > A poly-
morphism is associated with the presence of erosions, with
patients carrying the GA/AA genotypes having fewer ero-
sions. Although the result of the meta-analysis is consis-
tent with the results of our primary study, it is important
to mention that there was significant heterogeneity in the
Table 2 Longitudinal regression of joint damage and
TNFA -308G > A genotype (n = 208)
Effect Estimate Standard error
(estimate)
P-value
Intercept 5.8 1.18 < 0.0001
Genotype GA+AA -5.0 1.62 0.0020
Year 1.6 0.38 < 0.0001




Shown are the variables in the longitudinal regression analysis over 9 years,
with joint erosion score as the dependent variable and TNFA -308G > A or
TNFA -308G > A × year as primary dependent variables. Year2 allows for a
non-linear course of joint progression score over time. The analysis was
corrected for gender, and time-averaged 28-joint disease activity score
(DAS28), rheumatoid factor and age were not confounders.
Figure 1 Development of corrected joint scores over time
showing the GG and GA+AA genotypes, separately. Data points
were calculated using the mixed model (least-square means and
standard errors), including correction for age and 28-joint disease
activity score (DAS28).
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Table 3 Overview of the published studies included in the meta-analysis





Scoring method Definition erosive disease
Brinkman [2] Dutch 144 65 66.8 14.06 ns Erosions on any radiograph during first 3
years
Pawlik [10] Polish 91 63 51.7 (range 21-74)
#
4.7 ± 2.1 ns Erosions in chest, hands or feet
Khanna [9] Americans (Western US) and Mexican 189 76 ns 0.47 (0.3-0.71)* Sharp Erosion score ≥ 2 In hand/wrist or feet
Rezaieyazdi
[7]
Iranian 34 n.s. 47.3 ± 13.8 4.0 ± 3.7 ns Erosions in hands
Kazkaz [8] Syrian 156 80 44.02 ± 14.47 7.28 ± 4.87 Larsen Destruction score ≥ 2, right wrist
Kazkaz [8] French 512 75 57.56 ± 14.67 10.05 ± 8.66 Larsen Destruction score ≥ 2, right wrist
Ates [5] Turkish 98 80 50.8 ± 12 ns ns Erosions in hands or feet
Nemec [6] Caucasians from Moravian regions of the Czech
Republic
130 75 56.21 (20.25-79)* 11.08 (2.08-50.17)* Steinbrocker Erosions of stage II-IV in hands
Reneses [4] Spanish 134 70 50.4 ± 1.3 < 1 Sharp van der
Heijde
Erosion at 1 year in hands, wrist or feet
Hussein [3] Egyptian 172 100 47.4 ± 9.3 10.65 ± 7.9 Sharp ≥ 1 erosions in peripheral joints (hands or
feet)
Mosaad [1] Egyptian 122 80 39.9 ± 10.3 5.9 ± 5.1 Steinbrocker Erosions in hands















studies included in the meta-analysis (I2 = 53%). This
could be caused by differences in study design, mean dura-
tion of RA, sample size and ethnicity. An additional reason
is the assessment of the presence of erosions, which was
assessed in radiographs of different joints (see Table 3),
though most studies included erosions in the hands. Also
the definition of erosive disease differed between the stu-
dies, but the outcome used in the current study was the
presence of any erosion in the joints examined. As we
observed heterogeneity we also performed a random-
effects meta-analysis. This yielded a similar OR but, as
expected, a larger CI. Even so, both analyses point to a
modest effect of the polymorphism on the development of
joint damage.
In this study we also assessed whether the difference in
radiologic joint damage between G- homozygotes and A-
allele carriers could be explained by TNFA allele-specific
differences in mRNA expression. Many studies have
focused on the potential allele-specific expression of the
TNFA gene and TNFa production. Helmig and co-work-
ers reported that the -308G allele is associated with
TNFA expression in a cohort of 178 healthy subjects
[23]. In contrast, a recent meta-analysis in which 1,825
healthy subjects were investigated, reported no associa-
tion between the -308G > A polymorphism and TNF
protein and mRNA levels [25]. However, this might still
be the case for persons suffering from a disease. For
instance, the study of Muoz-Valle, et al. (50 patients with
osteoarthritis), and the study of Oregon-Romero, et al.
(50 patients with RA) both report an association between
the -308G allele and higher TNFA expression levels com-
pared to the -308A allele [21,22]. Nonetheless, our study
does not support this hypothesis and shows that the
effect of the -308G > A variant on joint damage is not
explained by allele-dependent expression in RA. Linkage
disequilibrium (LD) could be an overall factor to explain
this incongruent result if we assume that the -308G > A
variant is not functional. In fact, LD is strong in this area
of the genome, and it is difficult to study the role of a sin-
gle nucleotide polymorphism (SNP) in this region.
Figure 2 Meta-analysis results for the TNF -308G > A variant. Events indicate the number of patients with genotype GA or AA. M-H, Mantel-
Haenszel.
Figure 3 Relative expression of the TNFA gene per genotype
group. The GA genotype group (n = 15) and the AA genotype
group (n = 2) were combined and compared to the GG genotype
group (n = 49). No difference in TNFA expression was observed
between the GG group and the GA+AA group (p = 0.420).
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Nevertheless, a published haplotype analysis including
three SNPs (-857C > T, -308G > A, and -238G > A) in
the promoter of the TNFA gene also showed no associa-
tion between the SNPs and circulating TNF levels or
TNFA mRNA expression [25]. It is known that the LD in
the TNFA region even extends much further and is in
strong LD with the shared epitope (SE) [31]. This could
explain some of the inconsistency in the findings,
although the results of a study of Khanna and co-workers
indicates an effect of the -308G > A polymorphism on
joint damage progression independently of the SE [9].
Our patients are not genotyped for the SE and we could
not stratify for SE.
Conclusions
Our data support an association between the TNFA
-308GG genotype and joint damage, but not with dis-
ease activity or TNFA expression. Our meta-analysis
shows that the effects of this polymorphism are modest,
which makes it unsuitable as a single predictive marker
for disease severity.
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